OQROGet OQRO Pro
Insider trade

Eli Lilly (LLY)Officer sold ~$2.37M

Donald A Zakrowski, Officer at Eli Lilly, sold ~$2.37M of Eli Lilly shares.

~$2.37M
Approx. value · 2,000 sh @ $1,185.01
1,525.89
Holds after · shares reported
Traded
Aug 10, 2026
Filed
Aug 11, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 2, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  2. Jan 2, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  3. Mar 27, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  4. Jun 10, 2026Insider · Their largest sale since 2022Officer sold ~$2.88M of LLY shares in the open market
  5. Jun 10, 2026Congress · 1 personMembers of Congress: 2 purchases
  6. Jul 1, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  7. Jul 10, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  8. Jul 13, 2026FDAFDA drug approval: Verzenio
  9. Jul 14, 2026FDAFDA drug approval: Retevmo
  10. Jul 14, 2026FDAFDA drug approval: Retevmo
  11. Jul 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.6%
  12. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
  13. Aug 7, 2026InsiderOfficer sold ~$5.95M of LLY shares in the open market
  14. Aug 10, 2026 · this disclosureInsider · Their largest sale since 2014Officer sold ~$2.37M of LLY shares in the open market

What came next

  1. Aug 17, 2026Federal contract · $5K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $4.5K obligated to date
  2. Aug 17, 2026Insider · Their largest sale since 2022Officer sold ~$7.64M of LLY shares in the open market
  3. Aug 26, 2026FDAFDA drug approval: Zepbound
  4. Aug 27, 2026FDAFDA drug approval: Mounjaro
  5. Aug 27, 2026FDAFDA drug approval: Mounjaro
  6. Sep 18, 2026FDAFDA drug approval: Inluriyo
  7. Sep 18, 2026FDAFDA drug approval: Verzenio
  8. Sep 23, 2026FDAFDA drug approval: Onswik
  9. Sep 25, 2026FDAFDA drug approval: Olumiant
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Donald A Zakrowski, SVP, Finance, & CAO

The full history of Donald A Zakrowski, SVP, Finance, & CAO is on the profile page.

How this filing works

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data